Novel Dual-Action Targeted Nanomedicine in Mice With Metastatic Thyroid Cancer and Pancreatic Neuroendocrine Tumors

Journal of the National Cancer Institute
Naris NilubolElectron Kebebew

Abstract

The advantages of nanomedicines include preferential delivery of the payload directly to tumor tissues. CYT-21625 is the novel, first-in-class gold nanomedicine designed to target tumor vasculature and cancer cells by specifically delivering recombinant human tumor necrosis factor alpha (rhTNF) and a paclitaxel prodrug. We analyzed TNF receptor expression in publicly available gene expression profiling data and in thyroid tissue samples. Mice with metastatic FTC-133 and 8505C xenografts and the MEN1 conditional knock-out mice were treated weekly with CYT-21625 and gold nanoparticles with rhTNF only (CYT-6091); controls included mice treated with either paclitaxel or saline. In vivo luciferase activity was used to assess the effects on tumor growth. Computed tomography, magnetic resonance imaging, and 18F-Fludeoxyglucose positron emission tomography were used to study tumor selectivity in mice with insulin-secreting pancreatic neuroendocrine tumors (PNETs). All statistical tests were two-sided. Anaplastic thyroid cancer (ATC) expressed statistically significantly higher levels of TNF receptor superfamily 1A and 1B messenger RNA (n = 11) and protein (n = 6) than control samples (n = 45 and 13, respectively). Mice (n = 5-7 per gro...Continue Reading

References

Feb 27, 1971·British Medical Journal·H J Richards
May 1, 1971·British Medical Journal·F E Graham-Bonnalie
Oct 1, 1994·Journal of Pharmaceutical Sciences·S V BalasubramanianR M Straubinger
Nov 1, 1996·Seminars in Surgical Oncology·H R AlexanderD L Bartlett
Dec 26, 2001·Nucleic Acids Research·Ron EdgarAlex E Lash
May 8, 2002·The Journal of Clinical Endocrinology and Metabolism·Enrico PapiniClaudio M Pacella
Jun 5, 2003·Technology in Cancer Research & Treatment·Timo L M ten Hagen, A M M Eggermont
Jun 19, 2004·Drug Delivery·Giulio F PaciottiLawrence Tamarkin
Oct 29, 2004·Nature Reviews. Cancer·Carl-Henrik HeldinArne Ostman
Sep 1, 2005·Head & Neck
Dec 31, 2005·Yonsei Medical Journal·Hang-Seok ChangCheong Soo Park
Apr 15, 2006·The Oncologist·Remco van HorssenAlexander M M Eggermont
May 11, 2006·JAMA : the Journal of the American Medical Association·Louise Davies, H Gilbert Welch
Sep 12, 2007·Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract·Karl Y BilimoriaDavid J Bentrem
May 30, 2008·Endocrine-related Cancer·Thorvardur R HalfdanarsonGloria M Petersen
Dec 10, 2009·Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract·Jan FrankoA James Moser
Sep 30, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Steven K LibuttiLawrence Tamarkin
Dec 21, 2010·Seminars in Oncology·Kjell Oberg
Feb 11, 2011·The New England Journal of Medicine·Eric RaymondPhilippe Ruszniewski
Feb 11, 2011·The New England Journal of Medicine·James C YaoUNKNOWN RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group
Aug 21, 2012·Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals·Michael P GamcsikO Michael Colvin
Oct 12, 2012·Indian Journal of Gastroenterology : Official Journal of the Indian Society of Gastroenterology·Shailesh V ShrikhandeSavio G Barreto
Nov 8, 2012·Thyroid : Official Journal of the American Thyroid Association·Robert C SmallridgeUNKNOWN American Thyroid Association Anaplastic Thyroid Cancer Guidelines Taskforce
Nov 20, 2012·Surgery·Electron Kebebew
Jan 4, 2013·Science Translational Medicine·Crescent R IshamKeith C Bible
Jul 28, 2013·Thyroid : Official Journal of the American Thyroid Association·Hafiz Muhammad AliLiliane Massaad-Massade
Oct 8, 2013·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jason S EllisHelen Braley-Mullen
Nov 12, 2013·Current Problems in Surgery·Geoffrey W Krampitz, Jeffrey A Norton
Nov 23, 2013·Thyroid : Official Journal of the American Thyroid Association·Lisa ZhangElectron Kebebew
May 20, 2014·Biomaterials·Donatella PaolinoMassimo Fresta
Jan 28, 2015·Lancet·Alberto GabizonPiotr Grodzinski
Feb 12, 2015·The New England Journal of Medicine·Martin SchlumbergerSteven I Sherman
Oct 3, 2015·AJNR. American Journal of Neuroradiology·J T SkinnerC C Quarles
Oct 16, 2015·International Journal of Radiation Oncology, Biology, Physics·Nathan A KoonceRobert J Griffin
Sep 9, 2017·International Journal of Nanomedicine·Jianfeng GuoCaitriona M O'Driscoll

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Islet Cell

Islet Cell Carcinoma or Pancreatic Neuroendocrine Tumours arises in the hormone producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on Islet Cell Carcinoma here.

Carcinoma, Islet Cell (Keystone)

Islet Cell Carcinoma or Pancreatic Neuroendocrine Tumours arise in the hormone producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on islet cell carcinoma in this feed.

Cancer Cell Invasion: Nanomedicine

Nanomedicine is a promising alternative for cancer detection and therapy that utilizes nanoparticles, such as liposomes. Nanoparticles can potentially target cancer cell invasion and metastasis. Discover the latest research on Cancer Cell Invasion: Nanomedicine here.

Adenoma, Islet Cell

Islet Cell Adenoma arises in the islet cells, which are insulin producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on Islet Cell Adenoma here.